Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Human Vaccines

Volumn 5, Issue 6, 2009, Pages 414-419

  Narang, Anil ^a   Bose, Anuradha ^b   Pandit, Anand Nilkanth ^c   Dutta, Phalguni ^d   Kang, Gagandeep ^b   Bhattacharya, Sujit Kumar ^d   Datta, Sanjoy Kumar ^e   Suryakiran, P V ^e   Delem, Andrée ^e   Han, Htay Htay ^e   Bock, Hans Ludwig ^e  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c KEM HOSPITAL   (India)

^d NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Gastrointestinal disease; Immunogenicity; Reactogenicity; Rotavirus; Safety; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; PLACEBO; ROTAVIRUS VACCINE;

ANOREXIA; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INDIAN; INFANT; IRRITABILITY; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINORRHEA; SEROCONVERSION; SIDE EFFECT; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VOMITING;

EID: 70249090946     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.6.8176     Document Type: Article

References (24)

1. Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78:1246-55.
2. WHO position paper. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 32:285-96.
3. Jain V, Parashar UD, Glass RI, Bhan MK. Epidemiology of rotavirus in India. Indian J Pediatr 2001; 68:855-62.
4. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.
5. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1-20.
6. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1994; 169:900-4.
7. Parashar UD, Bresee JS, Gentsch JR, Glass RI. Rotavirus. Emerg Infect Dis 1998; 4:561-70.
8. Phukan AC, Patgiri DK, Mahanta J. Rotavirus associated acute diarrhoea in hospitalized children in Dibrugarh, north-east India. Indian J Pathol Microbiol 2003; 46:274-8.
9. Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16.
10. Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2836-42.
11. Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008; In press.
12. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27:1333-39.
13. Phua KB, Emmanuel SC, Goh P, Quak SH, Lee BW, Han HH, et al. A rotavirus vaccine for Infants: an Asian experience. Ann Acad Med Singapore 2006; 35:38-44.
14. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
15. Ruiz-Palacios GM, Pérez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
16. Bresee JS, El AS, Azim T, Chakraborty J, Mounts AW, Podder G, et al. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh. Pediatr Infect Dis J 2001; 20:1136-43.
17. Bhattacharya SK, Khalequzzaman Z, Jung-Soo K, Delem A, Damaso S, Han HH. Immune response in infants sero-positive at pre-vaccination: human rotavirus vaccine Rotarix™. Presented at WSPID 2007; Bangkok.
18. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718-31.
19. John S, Lalitha G, George K, Joseph A. Serological response to early measles vaccination. J Trop Pediatr 2004; 50:175-7.
20. Paul Y. OPV cannot eradicate polio from India: do we need any further evidence? Vaccine 2008; 26:2058-61.
21. Stein CE, Birmingham M, Kurian M, Duclos P, Strebel P. The global burden of measles in the year 2000 - a model that uses country-specific indicators. J Infect Dis 2003; 187:8-14.
22. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63.
23. World Health Organization. Progress towards interrupting wild poliovirus transmission, January 2006-May 2007. Wkly Epidemiol Rec 2007; 82:245-51.
24. van Doorn LJ, Keleter B, Hoefnagel E, Stainer I, Poliszczak A, Colau B, et al. Detection and genotyping of human rotavirus vp4 and vp7 genes in stool samples by reverse transcriptase PCR and reverse hybridization. Presented at Double Stranded RNA Virus meeting, Cape Town, South Africa 2006.